Cel Sci CVM
NYSE CVM
$1.45 -0.01 (-1.03%)
As of: Aug 21, 2026 · 3:31 PM EDT

Cel Sci (CVM) Non-Current Deferred Tax Liability (2015 - 2023)

Cel Sci (CVM) posted Non-Current Deferred Tax Liability of $2.7 million for Q3 2023, down 17.49% sequentially from $3.3 million in Q3 2022, and down 17.49% YoY from $3.3 million in Q3 2022.

Cel Sci (CVM) Non-Current Deferred Tax Liability (2015 - 2023) Analysis & Trends

Cel Sci has reported Non-Current Deferred Tax Liability for 9 years, with the latest figure at $2.7 million in Q3 2023.

  • Quarterly Non-Current Deferred Tax Liability fell 17.49% year-over-year to $2.7 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $2.7 million (down 17.49% YoY) and the FY2023 annual result came in at $2.7 million, down 17.49% from the prior year.
  • Non-Current Deferred Tax Liability eased to $2.7 million in Q3 2023 per CVM's latest filing, from $3.3 million in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $4.1 million in Q3 2020 and troughed at -$586000.0 in Q3 2019.
  • A 5-year average of $2.7 million and a median of $3.3 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
  • The sharpest annual moves came in 2019 and 2020: Non-Current Deferred Tax Liability plunged 192.43% in 2019, then surged 796.25% in 2020.
  • Over 5 years, Non-Current Deferred Tax Liability stood at -$586000.0 in 2019, then soared by 796.25% to $4.1 million in 2020, then retreated by 2.99% to $4.0 million in 2021, then retreated by 16.93% to $3.3 million in 2022, then retreated by 17.49% to $2.7 million in 2023.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $2.7 million, $3.3 million, and $4.0 million for Q3 2023, Q3 2022, and Q3 2021 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.83 Bn 130.98 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.79 Bn 77.79 Bn 3.93 Bn
3 Argenx Se 64.95 Bn 59.77 Bn 1.37 Bn
4 Moderna 58.59 Bn 53.46 Bn 52.00 Mn
5 BeOne Medicines 41.93 Bn 36.83 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.52 Bn 28.21 Bn 992.69 Mn
7 BioNTech SE 27.98 Bn 9.58 Bn 668.28 Mn
8 Insmed 27.42 Bn 26.26 Bn 358.27 Mn
9 Royalty Pharma 27.33 Bn 26.49 Bn -
10 Cel Sci 2.13 Mn -4.40 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2023 2.71 Mn
Sep 30, 2023 2.71 Mn
Sep 30, 2022 3.29 Mn
Sep 30, 2022 3.29 Mn
Sep 30, 2021 3.96 Mn
Sep 30, 2021 3.96 Mn
Sep 30, 2020 4.08 Mn
Sep 30, 2020 4.08 Mn
Sep 30, 2019 -586,000.00
Sep 30, 2019 -586,000.00
Sep 30, 2018 634,000.00
Sep 30, 2018 634,000.00
Sep 30, 2017 523,000.00
Sep 30, 2017 523,000.00
Sep 30, 2016 49,000.00
Sep 30, 2016 49,000.00
Sep 30, 2015 -86,000.00
Sep 30, 2015 -86,000.00